MGMT-Methylation in Non-Neoplastic Diseases of the Central Nervous System.

ABSTRACT: Quantifying O⁶-methylguanine-DNA methyltransferase (MGMT) promoter methylation plays an essential role in assessing the potential efficacy of alkylating agents in the chemotherapy of malignant gliomas. MGMT promoter methylation is considered to be a characteristic of subgroups of certain malignancies but has also been described in various peripheral inflammatory diseases. However, MGMT promoter methylation levels have not yet been investigated in non-neoplastic brain diseases. This study demonstrates for the first time that one can indeed detect slightly enhanced MGMT promoter methylation in individual cases of inflammatory demyelinating CNS diseases such as multiple sclerosis and progressive multifocal leucencephalopathy (PML), as well as in other demyelinating diseases such as

SUBMITTER: Teuber-Hanselmann S 

PROVIDER: S-EPMC8068191 | biostudies-literature | 2021 Apr

REPOSITORIES: biostudies-literature